Recombinant Rhesus CD22 protein, Fc-tagged, R-PE labeled
Cat.No. : | CD22-8854CP |
Product Overview : | Recombinant Rhesus CD22 protein, Fc-tagged was Conjugated with NH2-Reactive R-PE(R-Phycoerythrin). |
- Specification
- Gene Information
- Related Products
Description : | NH2-Reactive R-Phycoerythrin is used for antibody conjugation for immunostaining and cellular proteins for tracing. NH2-Reactive R-Phycoerythrin has succinimidyl ester groups, and can easily make a covalent bond with amino groups of protein without any activation process. |
Source : | HEK293 |
Species : | Rhesus |
Tag : | Fc |
Form : | Liquid in sterile PBS buffer pH 7.4 (may contains tiny amount of reaction buffer and R-Phycoerythrin). |
Endotoxin : | <1EU/ug by LAL method. |
Stability : | Sample is stable for at least 12 months when stored at -20 to -80°C from date of manufacture. For longer storage, add equal volume of glycerol to the sample solution and store at -20 to -80°C. |
Storage : | Store under sterile conditions at -20 to -80°C immediately after receipt. It is recommended that the protein be aliquoted for optimal storage. Avoid freeze-thaw cycles. |
Related Product : | CD22-8854C |
Official Symbol : | CD22 |
Synonyms : | CD226; CD226 molecule; CD226 antigen; |
Official Symbol : | CD22 |
Synonyms : | CD226; CD226 molecule; CD226 antigen; |
Products Types
◆ Lysates | ||
CD22-001MCL | Recombinant Mouse CD22 cell lysate | +Inquiry |
CD22-1956HCL | Recombinant Human CD22 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionCD22-targeted immunotherapy is more targeted, specifically attacking cancer cells, whereas chemotherapy affects both healthy and cancerous cells.
Yes, CD22-targeted therapies are often used in combination with chemotherapy or other immunotherapies for enhanced efficacy.
CD22-targeted therapies are being explored for autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.
Yes, CD22 is targeted in immunotherapy for B cell malignancies like acute lymphoblastic leukemia (ALL).
CD22 acts as an inhibitory receptor, regulating B cell activation and signaling.
Customer Reviews (3)
Write a reviewThe CD22 protein offers numerous advantages in trials and research studies, making it an excellent choice for scientists in need of reliable and high-quality experimental materials.
Its unique properties make CD22 an invaluable tool for investigating cellular signaling pathways, protein-protein interactions, and membrane dynamics.
With the CD22 protein and its accompanying technical assistance, I am confident that I can achieve successful outcomes for my research endeavors.
Ask a Question for All CD22 Products
Required fields are marked with *
My Review for All CD22 Products
Required fields are marked with *
Inquiry Basket